Surge

SURGE Therapeutics is developing a biodegradable hydrogel system for local intraoperative delivery of cancer immunotherapies at the time of surgical tumor resection, based on Harvard Medical School research; available public information focuses on preclinical development and translation toward clinical trials, without disclosed clinical trial outcomes yet.[1] Surge Laboratories operates as a cGMP-compliant CDMO specializing in microencapsulated APIs and coated granules/pellets.[2] Surge Biotech markets a broad portfolio of branded generic medicines and healthcare products in India, with no publicly disclosed proprietary clinical-stage assets.[3][4][6][8][10][11]